Edwards Lifesciences acquires early-stage TMVR company Innovalve, no terms

Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement TMVR company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies TMTT product group, led by corporate vice president, Daveen Chopra…The acquisition is expected to close by the end of 2024.